The International Vaccine Institute (IVI) and the Sabin Vaccine Institute signed a memorandum of understanding (MOU) to “form a strategic alliance around research, development and advocacy among other stipulations.” The strategic alliance “will allow both organizations to benefit by complementing their current capabilities, such as focused disease areas and networks. In addition, the two organizations will collaborate to leverage their presence in different geographical regions, IVI in Asia and Africa and Sabin in the U.S. and Latin America.” IVI and Sabin said the MOU includes: 1) Mutual introduction for product development programs; 2) Joint grant applications for development projects; 3) Joint grant applications for advocacy; 4) Establishment of offices in respective headquarters upon request; 5) Provision of policy presence and education of respective governmental entities where each organization has a strong presence; 6) Collaboration on fundraising; 7) Sharing of resources and personnel in the areas of regulatory affairs and submissions, quality assurance, and contract resource organization inputs.
Dr. Christian Loucq, Director-General of IVI, said, “I am thrilled to be signing this agreement with Sabin. Sabin shares common values with IVI and we look forward to seeking means to promote effective and efficient ways to advocate vaccine development in, and introduction to, developing countries.” Michael W. Marine, CEO at Sabin, said, “The strategic alliance between Sabin and IVI will allow our two organizations to strengthen the core activities that are required to build out a pipeline of vaccines for the world’s poorest communities. We look forward to collaborating with IVI on fundamental organizational priorities, including fundraising and advocacy efforts.”